The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

Award-winning journalist Christiane Amanpour has revealed that her ovarian cancer has returned for the third time, saying she is under immunotherapy for treatment. Amanpour, who was first diagnosed in ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...

When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

MONTREAL, Oct. /CNW/ – Today, AbbVie (NYSE: ABBV) has announced that Canada’s Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...

Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib ...